Richard Whitley to Genetic Vectors
This is a "connection" page, showing publications Richard Whitley has written about Genetic Vectors.
Connection Strength
0.990
-
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol. 2012 May; 86(9):5304-13.
Score: 0.374
-
Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 1998 Jan; 5(1):121-30.
Score: 0.140
-
The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11313-8.
Score: 0.129
-
HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice. Vaccine. 2007 Sep 17; 25(37-38):6764-73.
Score: 0.068
-
Oncolytic HSV-1 for the treatment of brain tumours. Herpes. 2006 Nov; 13(3):66-71.
Score: 0.065
-
Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin Microbiol Infect. 2002 Sep; 8(9):551-63.
Score: 0.048
-
Herpes simplex viruses: is a vaccine tenable? J Clin Invest. 2002 Jul; 110(2):145-51.
Score: 0.048
-
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A. 2000 Feb 29; 97(5):2208-13.
Score: 0.041
-
Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol. 2000 Jan-Feb; 10(1):17-30.
Score: 0.040
-
Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. Oncogene. 2019 08; 38(34):6159-6171.
Score: 0.039